Drug intelligence / Profile preview

TLANDO XR

Development stage: Unknown
Lead developer: Lipocine
Modality: Small Molecules
Administration: Oral

Overview

TLANDO XR (LPCN 1111) is a next-generation, orally administered prodrug of testosterone formulated as testosterone tridecanoate, developed to provide once-daily testosterone replacement therapy (TRT) for male hypogonadism. Utilizing Lipocine’s proprietary solubilization technology (Lip'ral), it is designed for improved systemic absorption and convenience over existing therapies. Clinical studies have shown favorable safety, tolerability, and pharmacokinetic profiles, with no drug-related severe or serious adverse events detected. TLANDO XR represents an advancement over prior formulations, aiming to mitigate the limitations and transfer risks associated with topical testosterone replacement options.

Brand names: TLANDO XR
Other names: LPCN 1111LPCN1111LPCN-1111testosterone tridecanoate

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on TLANDO XR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLANDO XR.

Explore the full profile